Evommune (NYSE:EVMN) Share Price Breaks Above Fifty Day Moving Average – Should You Sell?

Shares of Evommune, Inc. (NYSE:EVMN – Get Free Report) passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $7.81 and traded as high as $8.09. Evommune shares last traded at $7.8750, with a volume of 843,159 shares traded.

Analyst Ratings Changes

EVMN has been the topic of several recent analyst reports. Needham & Company LLC initiated coverage on shares of Evommune in a report on Wednesday, August 26th. They set a “buy” rating and a $28.00 price objective on the stock. Leerink Partners lowered their target price on shares of Evommune from $28.00 to $22.00 and set an “outperform” rating for the company in a report on Wednesday, September 9th. Royal Bank Of Canada dropped their price target on shares of Evommune from $29.00 to $21.00 and set an “outperform” rating for the company in a research report on Wednesday, September 9th. Stifel Nicolaus set a $30.00 price target on shares of Evommune in a research report on Wednesday, September 9th. Finally, UBS Group started coverage on shares of Evommune in a research note on Sunday, October 11th. They set a “neutral” rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $30.80.

Check Out Our Latest Stock Report on EVMN

Evommune Price Performance

The stock has a 50-day simple moving average of $7.64 and a 200-day simple moving average of $17.17.

Evommune (NYSE:EVMN – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.03). Equities research analysts anticipate that Evommune, Inc. will post -3.35 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Alps Advisors Inc. boosted its holdings in Evommune by 30.6% during the third quarter. Alps Advisors Inc. now owns 47,737 shares of the company’s stock worth $394,000 after buying an additional 11,179 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Evommune in the second quarter valued at $634,000. Velan Capital Investment Management LP increased its holdings in shares of Evommune by 1.1% in the second quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company’s stock valued at $5,997,000 after buying an additional 5,000 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Evommune in the second quarter valued at $340,000. Finally, Defilade Capital Management L.P. lifted its position in shares of Evommune by 215.0% during the 1st quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock valued at $15,601,000 after acquiring an additional 463,171 shares during the last quarter.

About Evommune

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.

Recommended Stories

Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.